Key Insights

Highlights

Success Rate

81% trial completion

Published Results

199 trials with published results (24%)

Research Maturity

467 completed trials (57% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

13.8%

113 terminated out of 817 trials

Success Rate

80.5%

-6.0% vs benchmark

Late-Stage Pipeline

26%

214 trials in Phase 3/4

Results Transparency

43%

199 of 467 completed with results

Key Signals

199 with results81% success113 terminated

Data Visualizations

Phase Distribution

590Total
Not Applicable (134)
Early P 1 (5)
P 1 (85)
P 2 (152)
P 3 (146)
P 4 (68)

Trial Status

Completed467
Terminated113
Unknown82
Recruiting72
Withdrawn43
Active Not Recruiting23

Trial Success Rate

80.5%

Benchmark: 86.5%

Based on 467 completed trials

Clinical Trials (817)

Showing 20 of 20 trials
NCT05578508Phase 1Withdrawn

Stem Cells for the Treatment of Pouchitis

NCT05442567Phase 3Recruiting

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT06332534Phase 3RecruitingPrimary

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

NCT02636517Phase 1Enrolling By Invitation

Fecal Microbiome Transplant

NCT04073472Phase 1WithdrawnPrimary

Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's

NCT07531342Not ApplicableNot Yet RecruitingPrimary

Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease

NCT06430801Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06408935Phase 3RecruitingPrimary

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

NCT06581328Phase 4Recruiting

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

NCT06233461Phase 2RecruitingPrimary

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT07242248Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

NCT06663332Phase 3RecruitingPrimary

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

NCT05923073Phase 3RecruitingPrimary

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

NCT00606346Active Not RecruitingPrimary

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

NCT03466411Phase 2Active Not RecruitingPrimary

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

NCT07102368Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

NCT05242471Phase 2Active Not RecruitingPrimary

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT03345823Phase 3Active Not RecruitingPrimary

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT07250815Completed

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

NCT03167437Phase 1RecruitingPrimary

An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

Scroll to load more

Research Network

Activity Timeline